Synaptogenix (NASDAQ:TAOX) Releases Quarterly Earnings Results

Synaptogenix (NASDAQ:TAOX) announced its earnings results on Tuesday. The company reported $1.03 earnings per share for the quarter, FiscalAI reports. The company had revenue of ($2.46) million during the quarter.

Synaptogenix Price Performance

Shares of NASDAQ TAOX opened at $5.73 on Thursday. Synaptogenix has a one year low of $1.84 and a one year high of $11.98. The firm’s 50 day simple moving average is $4.67 and its two-hundred day simple moving average is $5.82. The stock has a market capitalization of $42.69 million, a P/E ratio of -0.28 and a beta of 1.67.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Wall Street Zen raised shares of Synaptogenix from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Synaptogenix in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Synaptogenix currently has an average rating of “Sell”.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.